Results 131 to 140 of about 26,025 (223)

GATA2 Mutations Predict Poor Prognosis in Transplanted Myeloid Neoplasms

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background GATA binding protein 2 (GATA2) plays a crucial role in the differentiation, proliferation, and maintenance of hematopoietic stem cells (HSCs). GATA2 mutations have been identified in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), but the impact of somatic GATA2 mutations on prognosis remains controversial ...
Xian Zhang, Bingjie Wang, Yujun Dong, Qingya Wang, Qian Wang, Jialin Zhu, Qingyun Wang, Na Han, Yuan Li   +8 more
wiley   +1 more source

Clinical Characteristics, Gene Mutation Profiles and Prognosis of Patients With Acute Myeloid Leukemia Carrying PHF6 Mutations

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Plant Homeodomain Finger Protein 6 (PHF6) gene mutations are rare in acute myeloid leukemia (AML), with unclear mechanisms and uncertain prognostic value. They may compromise risk stratification and treatment decisions. This study analyzed clinical features and survival outcomes in PHF6‐mutated AML patients, evaluating the impact of
Dongmei Wang, Hanzhang Pan, Yungui Wang, Huan Xu, Lin Liu, Yuting Xu, Hongyan Tong   +6 more
wiley   +1 more source

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress

Journal of Experimental & Clinical Cancer Research
Background Venetoclax + azacitidine is a frontline treatment for older adult acute myeloid leukemia (AML) patients and a salvage therapy for relapsed/refractory patients who have been treated with intensive chemotherapy.
Jenna L. Carter, Yongwei Su, Eman T. Al-Antary, Jianlei Zhao, Xinan Qiao, Guan Wang, Holly Edwards, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Steven A. Buck, Maik Hüttemann, Joshua E. Allen, Varun V. Prabhu, Jay Yang, Jeffrey W. Taub, Yubin Ge   +17 more
doaj   +1 more source

Targeting the nuclear export receptor exportin‐1 in acute myeloid leukaemia: From biology to clinical translation

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
• XPO1 hyperactivation promotes leukaemogenesis by altering nucleocytoplasmic transport and transcriptional control in acute myeloid leukaemia (AML). • Selinexor and eltanexor show preferential activity in NPM1‐mutated, DEK::NUP214‐positive and SF3B1‐mutated myeloid neoplasms.
Yifan Liu, Xiaoya Yun, Weidong Ding, Suxiao Li, Hui Liu   +4 more
wiley   +1 more source

Adding venetoclax or hypomethylating agents to induction chemotherapy as first-line treatment for adults with acute myeloid leukemia: a retrospective case-cohort study

Therapeutic Advances in Hematology
Background: The response rate of traditional first-line induction chemotherapy (IC) for newly diagnosed acute myeloid leukemia needs to be improved, but it is not clear whether adding venetoclax or hypomethylating agents (HMAs) to IC will improve the ...
Fangfei Xu, Kuangguo Zhou, Duanhao Gong, Wei Huang   +3 more
doaj   +1 more source

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models [PDF]

, 2016

core   +1 more source

Chronic lymphocytic leukemia with IGH::BCL3‐translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Approximately 1% of chronic lymphocytic leukemia (CLL) cases harbor a translocation juxtaposing the immunoglobulin heavy chain (IGH) and B‐cell lymphoma 3 (BCL3) loci. Aiming at comprehensive molecular characterization of IGH::BCL3‐positive B‐cell neoplasms, we here investigated samples from 84 patients using fluorescence in situ hybridization
Cosima Drewes, Cristina López, Juan Emilio Martinez‐Manjón, Nnamdi Okeke, Billy Jebaraj, Susanne Bens, Björn Brändl, Martin J. S. Dyer, Barbara Eichhorst, Anja Fischer, Kirsten Fischer, Sandra Robrecht, Michael Hallek, Selina Glaser, Sina Hillebrecht, Sandrine Jayne, Helene Kretzmer, Anja Mottok, Franz‐Josef Müller, Christof Schneider, Ole Ammerpohl, Coral del Val, Stephan Stilgenbauer, Eugen Tausch, Reiner Siebert   +24 more
wiley   +1 more source

Deciphering Bax Dynamics: Regulation, Retrotranslocation, and Mitochondrial Interplay in the Commitment to Apoptosis: A Narrative Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background The apoptotic pathway mediated by mitochondria depends on the activation of pro‐apoptotic Bcl‐2 proteins Bax and Bak. When they permeabilize the outer mitochondrial membrane (OMM), mitochondrial dysfunction occurs, leading to caspase activation.
Mehrin Haque Tanisha, Md. Ayman Siddique, Zubaier Ahmed, Nashrah Mustafa, Fariha Tasneem   +4 more
wiley   +1 more source

From Platelet Toxicity to Precision Targeting: Evolving Strategies to Overcome Thrombocytopenia in BCL‐2/BCL‐XL Inhibition

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Simultaneous blockade of the anti‐apoptotic proteins BCL‐2 and BCL‐XL has been shown to be efficacious in preclinical and clinical trials for tumors that are co‐dependent on their survival pathways, although clinical development has been limited owing to dose‐limiting thrombocytopenia associated with BCL‐XL inhibition.
Md Mohiuddin
wiley   +1 more source

Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications

MedComm, Volume 7, Issue 5, May 2026.
Mutant isocitrate dehydrogenase affects multiple cancer types. Alterations in IDH1 and IDH2 result in abnormal enzyme activity, leading to the overproduction of D‐2‐hydroxyglutarate (D‐2HG). This metabolite disrupts cellular metabolism and epigenetic regulation, driving cancer initiation, progression, and metastasis.
Yuhan Fang, Xiaoqing Wang, Kai Luo, Tikam Chand Dakal, He Bai, Caiming Xu, Guixin Zhang   +6 more
wiley   +1 more source